An initial analysis of the international Phase II/III trial (DIAN-TU) evaluating solanezumab and gantenerumab in people in the early stages of a rare and inherited form of Alzheimer’s disease has yielded disappointing results.
The US FDA has given the green light to Biogen (MA, USA) to proceed with the Phase IIIB re-dosing study of aducanumab for patients with Alzheimer’s disease.
Researchers have developed an artificial intelligence algorithm that can identify molecular patterns specific to Alzheimer’s and Huntington’s disease. This study could lead to a more individualized approach to neurodegenerative disease treatment.
A recently published study has indicated that lithium, in doses of up to 400-times lower than what is currently being prescribed for mood disorders, could halt signs of advanced Alzheimer’s disease in rats.
A common mutation in a key enzyme involved in alcohol metabolism may increase damage in cells obtained from individuals with Alzheimer’s disease and in mice.
At the Clinical Trials on Alzheimer’s Disease Congress this week, Biogen (MA, USA) has provided a detailed report on the latest aducanumab results, including why there was such a difference in the results between ENGAGE and EMERGE.
Artificial neurons have been developed in a first-of-its-kind achievement that closely resemble biological neurons, mimicking their responses to a range of stimulations.
At SfN Neuroscience 2019, we had the brilliant opportunity of interviewing Hemraj Dodiya about sex-specific effects of microbiome perturbations in an Alzheimer’s mouse model.
Preclinical data has demonstrated that an oral small molecule drug could inhibit the formation of neurotoxic tau oligomers in an animal model most relevant to Alzheimer’s disease.
What are the challenges associated with identifying risk genes for Alzheimer’s disease? What more needs to be done to successfully translate this genetic data into potential therapeutics? Watch our video with Owen Peters to find out more.
